The FusioBio technology generates stable covalent trimers of tumor necrosis factor superfamily ligands to be used alone or in combination immunotherapy with other agents.
The FusionBio technology is unique in that it creates stable trimeric ligands with potent activity but without any external additions or introduced immunogenicity problems.
